Medicare Enrolled
Dr. Allison Gorrebeeck, MD
Hematology & Oncology · Austin, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Gorrebeeck from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Gorrebeeck? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Gorrebeeck
Dr. Allison Gorrebeeck is a hematology & oncology in Austin, TX, with 19 years in practice. Based on federal Medicare data, Dr. Gorrebeeck performed 81,644 Medicare services across 3,062 unique beneficiaries.
Between the years covered by Open Payments, Dr. Gorrebeeck received a total of $2,700 from 41 pharmaceutical and/or device companies across 121 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Gorrebeeck is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 11% volume in TX$ $2,700 industry payments
Medicare Practice Summary
Medicare Utilization ↗81,644
Medicare services
Top 11% in TX for hematology & oncology
3,062
Unique beneficiaries
$7
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~4,297 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) | 18,800 | $0 | $2 |
| Anti-nausea injection (fosaprepitant) | 18,450 | $0 | $5 |
| Oxaliplatin chemotherapy injection | 11,000 | $0 | $33 |
| Paclitaxel chemotherapy injection | 10,986 | $0 | $8 |
| Pembrolizumab injection (Keytruda) | 8,000 | $43 | $136 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 2,540 | $23 | $155 |
| Dexamethasone injection (steroid) | 2,105 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 1,510 | $1 | $114 |
| Injection, granisetron hydrochloride, 100 mcg | 700 | $0 | $24 |
| Complete blood count (CBC) with differential | 552 | $8 | $36 |
| Injection of additional new drug or substance into vein | 540 | $12 | $108 |
| Comprehensive metabolic blood panel | 499 | $10 | $64 |
| Blood draw (venipuncture) | 496 | $8 | $20 |
| Injection, carboplatin, 50 mg | 454 | $2 | $300 |
| Injection, fluorouracil, 500 mg | 386 | $2 | $13 |
| Administration of chemotherapy into vein, 1 hour or less | 308 | $106 | $707 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 305 | $20 | $128 |
| Injection, magnesium sulfate, per 500 mg | 286 | $1 | $6 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 263 | $23 | $157 |
| Office visit, established patient, complex (40-54 min) | 228 | $135 | $496 |
| Office visit, established patient (30-39 min) | 214 | $87 | $368 |
| Injection, potassium chloride, per 2 meq | 165 | $0 | $1 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 161 | $51 | $313 |
| Injection, zoledronic acid, 1 mg | 151 | $7 | $431 |
| Administration of additional new drug or substance into vein, 1 hour or less | 138 | $53 | $344 |
| Administration of chemotherapy into vein, each additional hour | 131 | $23 | $161 |
| Infusion, normal saline solution , 1000 cc | 121 | $2 | $19 |
| Injection, diphenhydramine hcl, up to 50 mg | 115 | $1 | $7 |
| Immunoglobulin level test | 114 | $9 | $56 |
| Lactate dehydrogenase (enzyme) level | 103 | $6 | $31 |
| Ferritin level test (iron stores) | 97 | $13 | $60 |
| Iron level test | 97 | $6 | $27 |
| Iron binding capacity test | 97 | $8 | $35 |
| Reticulated (young) platelet measurement | 93 | $35 | $143 |
| Office visit, established patient (20-29 min) | 93 | $62 | $250 |
| Unclassified drugs | 81 | $7 | $28 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 74 | $60 | $211 |
| Thyroid stimulating hormone (TSH) test | 71 | $16 | $80 |
| Measurement of immunoglobulin light chains | 68 | $17 | $60 |
| Drug injection, under skin or into muscle | 65 | $11 | $96 |
| Infusion into a vein for hydration, 31-60 minutes | 61 | $27 | $256 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 60 | $17 | $100 |
| Microscopic examination for white blood cells with manual cell count | 56 | $4 | $22 |
| Complete blood count (CBC), automated | 56 | $6 | $34 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 52 | $27 | $145 |
| Hospital follow-up visit, high complexity | 48 | $89 | $357 |
| Magnesium level test | 47 | $7 | $29 |
| Hospital follow-up visit, moderate complexity | 46 | $60 | $247 |
| Carcinoembryonic antigen (cea) protein level | 44 | $18 | $99 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 37 | $136 | $500 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 36 | $16 | $94 |
| Infusion into a vein for hydration, each additional hour | 35 | $10 | $75 |
| Injection, lorazepam, 2 mg | 35 | $1 | $3 |
| New patient office visit, complex (60-74 min) | 33 | $161 | $709 |
| Beta-2 microglobulin (protein) level | 31 | $16 | $96 |
| Administration of additional new drug or substance into vein using push technique | 31 | $45 | $289 |
| New patient office visit (45-59 min) | 30 | $121 | $565 |
| Free thyroxine (T4) test | 28 | $9 | $65 |
| Irrigation of implanted venous access drug delivery device | 28 | $19 | $114 |
| Vitamin B-12 level test | 27 | $15 | $76 |
| Folic acid level test | 26 | $14 | $73 |
| Thyroid hormone, t3 measurement, free | 26 | $17 | $90 |
| Protein measurement, serum | 18 | $11 | $99 |
| Red blood count, automated test | 18 | $4 | $23 |
| Immunologic analysis technique on serum | 18 | $29 | $108 |
| Immunologic analysis technique on serum (immunofixation) | 18 | $22 | $160 |
| Injection of drug or substance into vein | 16 | $31 | $247 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 15 | $92 | $657 |
| Flu vaccine administration | 11 | $31 | $58 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
0.9% high complexity
94.2% medium
4.9% routine
Industry Payment Transparency
Open Payments through 2024 ↗$2,700
Total received (2018-2024)
Avg $386/year across 7 years
Bottom 47% in TX for hematology & oncology
41
Companies
121
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,501 (92.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$199 (7.4%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$927
2023$388
2022$297
2021$155
2020$25
2019$199
2018$708
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$339
PFIZER INC.
$274
Tempus AI, Inc
$220
Amgen Inc.
$179
Celgene Corporation
$166
Takeda Pharmaceuticals U.S.A., Inc.
$152
Novartis Pharmaceuticals Corporation
$141
Bard Peripheral Vascular, Inc.
$110
Gilead Sciences, Inc.
$95
GENZYME CORPORATION
$91
Eisai Inc.
$80
Merck Sharp & Dohme LLC
$74
Seagen Inc.
$70
AstraZeneca Pharmaceuticals LP
$62
Merck Sharp & Dohme Corporation
$59
Genentech USA, Inc.
$52
Daiichi Sankyo Inc.
$43
Sysmex Inostics Inc
$41
Stemline Therapeutics Inc.
$38
E.R. Squibb & Sons, L.L.C.
$32
Coherus Biosciences Inc.
$28
Ipsen Biopharmaceuticals, Inc
$24
Alexion Pharmaceuticals, Inc.
$24
Incyte Corporation
$22
TAIHO ONCOLOGY, INC.
$22
Puma Biotechnology, Inc.
$21
GlaxoSmithKline, LLC.
$20
Lilly USA, LLC
$19
Helsinn Therapeutics (U.S.), Inc.
$18
Abbott Laboratories
$18
Octapharma USA, Inc.
$17
Regeneron Healthcare Solutions, Inc.
$17
ADC Therapeutics America, Inc.
$17
ARRAY BIOPHARMA INC
$17
Agios Pharmaceuticals, Inc.
$16
PUMA BIOTECHNOLOGY, INC.
$16
SHIELD THERAPEUTICS INC
$14
Pharmacyclics LLC, An AbbVie Company
$14
Boehringer Ingelheim Pharmaceuticals, Inc.
$13
Exelixis Inc.
$13
R-Pharm US LLC
$11
Top 3 companies account for 30.8% of total payments
Associated products mentioned in payments ›
ACCRUFER · ALOXI · ALUNBRIG · Abraxane · Avastin · BLENREP · BOSULIF · CYRAMZA · Cabometyx · DARZALEX · ELITEK · ENHERTU · Enhertu · Fabhalta · GILOTRIF · Halaven · Herceptin · IBRANCE · IMBRUVICA · IMLYGIC · INJECTAFER · Imbruvica · Ixempra · JADENU · JAKAFI · KEYTRUDA · KISQALI · Kyprolis · LIBTAYO · LONSURF · Lenvima · MYLOTARG · NINLARO · OCTAGAM · OPDIVO · Onivyde · Orserdu · PADCEV · PROCLAIM · Pomalyst · REBLOZYL · RYDAPT · SARCLISA · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TIVDAK · TUKYSA · Trodelvy · ULTOMIRIS · Udenyca · XALKORI · XTANDI
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (93%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $3 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
32
Per 100K population
2.4
County median income
$97,169
Nearest hospital
NORTH AUSTIN MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Gorrebeeck is a mixed practice specialist, with above-average Medicare volume (top 11% in TX), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Gorrebeeck experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Gorrebeeck performed 18,800 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Gorrebeeck receive payments from pharmaceutical companies?
Yes. Dr. Gorrebeeck received a total of $2,700 from 41 companies across 121 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Gorrebeeck's costs compare to other hematology & oncologys in Austin?
Dr. Gorrebeeck's average Medicare payment per service is $7. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Gorrebeeck) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Austin
Browse hematology & oncologys in Austin ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in TX
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in TX
Which TX hematology & oncologys receive the most from drug and device companies.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
By company
Tempus AI, Inc Payments to Doctors
See all physicians who received payments from Tempus AI, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology